Skip to main content
SpringerLink
Log in

AmBisome®: Long Circulating Liposomal Formulation of Amphotericin B

  • Chapter
Long Circulating Liposomes: Old Drugs, New Therapeutics

Part of the book series: Biotechnology Intelligence Unit ((BIOIU))

Abstract

AmBisome® is a newly commercialized formulation of amphotericin B incorporated into small unilamellar liposomes composed of cohesive bilayer forming lipids (see chapter 1). An important feature of this formulation is that the amphotericin B is stably incorporated into the liposome bilayer.1 In recent years, this and other lipid formulations have been devised to improve the utility of Fungizone, a micellar formulation of amphotericin B which rapidly disassociates upon iv administration. While the standard formulation is proven clinically, it is limited by severe renal toxicity, and many life-threatening fungal infections cannot successfully be treated.2,3 For the purposes of this chapter, Fungizone is considered “free” amphotericin B (ampB) administration.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler-Moore J, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome,® a unilamellar liposomal formulation of amphotericin B. J Liposome Research 1993; 3(3)429–45o.

    Google Scholar 

  2. Utz JP. Amphotericin B toxicity: general side effects. Ann Int Med 1964; 61: 340–354.

    Article  PubMed  CAS  Google Scholar 

  3. McCurdy KK, Frederic M, Elkinton JR. Renal tubular acidosis due to amphotericin B. N Eng J Med 1968; 278: 124–131.

    Article  CAS  Google Scholar 

  4. Proffitt RT, Adler-Moore J, Fujii G et al. Stability and mode of action of AmBisome (liposomal amphotericin B). J Controlled Release 1994; z8: 342–343.

    Article  Google Scholar 

  5. McAndrews BJ, Lee MJA, Adler-Moore JP. Comparative toxicities of fungizone and AmBisome for cultured kidney cells and macrophages. General Proceeding of the ASM Meeting for American Society for Microbiology. Atlanta, Georgia 1993:11 (Abstract).

    Google Scholar 

  6. Proffitt RT, Satorius A, Chiang S et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrobial Chemotherapy. 1991; 28 (Suppl. B): 49–61.

    Article  CAS  Google Scholar 

  7. Fielding RM, Singer AW, Wang LH et al. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrobial Agents Chemotherapy 1992; 36: 299–307.

    Article  CAS  Google Scholar 

  8. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrobial Chemotherapy 1991; 28 (suppl B): 83–91.

    Article  Google Scholar 

  9. Ringden O, Andstrom E, Remberger M et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplantation 1994; 14 (Supp1.5): S10 - S14.

    PubMed  Google Scholar 

  10. Turner AF, Presant CA, Proffitt RT et al. In-in-labeled liposomes: dosimetry and tumor depiction. Radiology 1988; 166 (3): 761–765.

    PubMed  CAS  Google Scholar 

  11. Lee JW, Amantea MA, Francis PA et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrobial Agents Chemotherapy 1994; 38 (4): 713–718.

    Article  CAS  Google Scholar 

  12. Hiles R, Bekersky I. Pharmacokinetics (PK) of liposomal amphotericin B (AmBisome) in rats. Pharmaceutical Research 1993; 10(1o):S-372 (Abstract #PPDM 8295).

    Google Scholar 

  13. Bekersky I, Hiles R. Pharmacokinetics (PK) of liposomal amphotericin B (AmBisome) in dogs. Pharmaceutical Research 1993; io(1o):S-372 (Abstract # PPDM 8296).

    Google Scholar 

  14. Walsh TJ, Bekersky I, Yeldandi V et al. Pharmacokinetics of AmBisome in persistently febrile neutropenic patients receiving empirical antifungal therapy. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract A13. 1995: 3.

    Google Scholar 

  15. Croft SL, Davidson RNN, Thorton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrobial Chemotherapy 1991; 28 (Suppl

    Google Scholar 

  16. Gangneux JP, Sulahian A, Garin Y et al. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrobial Agents Chemotherapy 1996; 4o (5): 1214–1218.

    Google Scholar 

  17. Van Etten EWM, Van den Heuvel-de Groot C, Bakker-Woudenberg, IAJM. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and Fluconazole in the treatment of systemic candidosis in immunocompetent and leukopenic mice. J Antimicrobial Chemotherapy 1993; 32: 723–739.

    Article  Google Scholar 

  18. Adler-Moore JP, Chiang S, Satorius A et al. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrobial Chemotherapy 1991; 28 (Suppl. B): 63–71.

    Article  CAS  Google Scholar 

  19. Karyotakis NC, Anaissie, E J. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrobial Agents Chemotherapy 1994; 38 (11): 2660–2662.

    Article  CAS  Google Scholar 

  20. Francis P, Lee JW, Hoffman A et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of D-mannitol and galactomannan as markers of infection and therapeutic response. J Infectious Diseases 1994; 169: 356–368.

    Article  CAS  Google Scholar 

  21. Allen SD, Sorenson KN, Nejdl MJ et al. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemotherapy 1994; 34: 1001–1013.

    Article  CAS  Google Scholar 

  22. Albert MM, Stahl-Carroll TL, Luther MF et al. Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J Mycol Med 1995; 5: 1–6.

    Google Scholar 

  23. Graybill JR, Boccanegra R. Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrobial Agents Chemotherapy 1995; 39 (8): 1885–1887.

    Article  CAS  Google Scholar 

  24. Clemons KV, Stevens DA. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J Antimicrobial Chemotherapy 1993; 32: 465–472.

    Article  CAS  Google Scholar 

  25. Clemons KV, Stevens DA. Comparison of a liposomal amphotericin B formulation (AmBisome) and desoxycholate amphotericin B (Fungizone) for the treatment of murine paracoccidioidomycosis. J Med Vet Mycol 1993; 31: 387–394.

    Article  Google Scholar 

  26. Garcia AL. Efficacy of single high dose AmBisome for treatment of murine candidiasis and histoplasmosis. Masters thesis. Pomona CA: California State Polytechnic University, Pomona, 1996;

    Google Scholar 

  27. Prentice HG, Catovsky D, Aoun M et al. AmBisome versus amphotericin B in patients with fever unresponsive to antibiotic therapy for 96 h, or with confirmed fungal infection. 2nd International Symposium on Febrile Neutropenia. 1995; Abstract 35.

    Google Scholar 

  28. Hann IM, Stevens RF, Pinkerton CR et al. Safety and efficacy of two dose regimes of AmBisome versus amphotericin B as empiric antifungal treatment in neutropenic pediatric patients. n“ Annual Meeting of the European Group for Blood & Bone Marrow Transplantation & 11th Meeting of the Nurses Group, Davos, Switzerland, 1995; Abstract.

    Google Scholar 

  29. Ringden O, Meunier F, Tollemar J et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrobial Chemotherapy 1991; 28 (suppl B): 73–82.

    Article  Google Scholar 

  30. Tollemar J, Ringden O, Tyden G. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and Safety Evaluation. Clinical Transplantation 1990; 4: 167–175.

    Google Scholar 

  31. Mills W, Chopra R, Linch DC et al. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. British Journal Haematology 1994; 86: 754–760.

    Article  CAS  Google Scholar 

  32. Schurmann D, De Matos Marques B, Grunewald T et al. Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated cryptococcosis. J Infectious Diseases 1991; 164: 620.

    Google Scholar 

  33. Coker RJ, Viviani M, Gazzard BG et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993; 7: 829–835.

    Article  PubMed  CAS  Google Scholar 

  34. Leenders ACAP, Reiss P, Portegies P et al. A randomized trial of liposomal amphotericin B (AmBisome) 4 mg/kg versus amphotericin B o.7 mg/kg for cryptococcal meningitis in HIV infected patients. Proceedings of the 36th Interscience Conference on Antimicrobial Agents Chemotherapy. 1996; Abstract LM35.p z87.

    Google Scholar 

  35. Viviani MA, Cofrancesco E, Boschetti C et al. Eradication of Fusarium infection in a leukopenic patient treated with liposomal amphotericin B. Mycoses 1991; 34: 255.

    Article  PubMed  CAS  Google Scholar 

  36. Fisher EW, Toma A, Fisher PH et al. Rhinocerebral mucormycosis: use of liposomal amphotericin B. J Laryngology and Otology 1991; 105: 575.

    Article  CAS  Google Scholar 

  37. Seaman J, Boer C, Wilkinson R et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Inf Dis 1995; 21: 188–193.

    Article  CAS  Google Scholar 

  38. Emminger W, Graninger W, Emminger-Schmidmeier W et al. Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer. Ann Hematol 1994; 6827–31.

    Google Scholar 

  39. Zoubek A, Emminger W, Emminger-Schmidmeier W et al. Conventional vs. liposomal amphotericin B in immunosuppressed children. Pediatric Hematology Oncology 1992; 9: 187–190.

    Article  CAS  Google Scholar 

  40. Bindschadler DD, Bennett JE. A pharmacologic guide to the clinical use of amphotericin B. J Infectious Diseases 1969; 120(4)427–436.

    Google Scholar 

  41. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clinical Pharmacokinetics 1983; 8: 17–42.

    Article  PubMed  CAS  Google Scholar 

  42. Anaissie E, Paetznick V, Proffitt R et al. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1991; 10: 665–668.

    Article  PubMed  CAS  Google Scholar 

  43. Garcia AL, Satorius A, Proffitt RT et al. Prophylaxis with single high dose AmBisome (AmBi) minimizes murine histoplasmosis and candidiasis. Abstract, 95`s General Meeting of the American Society for Microbiology, Washington DC 1995: i64.

    Google Scholar 

  44. Karyotakis NC, Anaissie EJ, Hachem R et al. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J Infectious Diseases 1993; 168: 1311–1313.

    Article  CAS  Google Scholar 

  45. Anaissie EJ, Hachem R, Karyotakis NC et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrobial Agents Chemotherapy 1994; 38 (11): 2541–2544.

    Article  CAS  Google Scholar 

  46. Albert MM, Adams K, Luther MJ et al. Efficacy of AmBisome in murine coccidioidomycosis. J Med Vet Mycol 1994; 32: 467–471.

    Article  PubMed  CAS  Google Scholar 

  47. Adler-Moore JP. AmBisome targeting to fungal infections. Bone Marrow Transplantation 1994; 14 (Suppl 5): S3 - S7.

    PubMed  Google Scholar 

Download references

Authors
  1. Jill P. Adler-Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard T. Proffitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Genetic Therapy, Inc., Gaithersburg, Maryland, USA

    Martin C. Woodle Ph.D.

  2. Department of Pharmaceutics, University of Utrecht, Utrecht, The Netherlands

    Gerrit Storm Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Adler-Moore, J.P., Proffitt, R.T. (1998). AmBisome®: Long Circulating Liposomal Formulation of Amphotericin B. In: Woodle, M.C., Storm, G. (eds) Long Circulating Liposomes: Old Drugs, New Therapeutics. Biotechnology Intelligence Unit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22115-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-22115-0_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-22117-4

  • Online ISBN: 978-3-662-22115-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation